Azurity Pharmaceuticals is a specialty pharmaceutical company dedicated to developing innovative, high-quality medicines for overlooked patient populations, including pediatric and geriatric patients. Founded in May 2019 through the acquisition of Silvergate Pharmaceuticals by CutisPharma, the company is headquartered in Woburn, Massachusetts, with manufacturing facilities in Wilmington, MA. Azurity has a global presence in over 50 countries and offers a diverse portfolio of more than 50 medicines across various dosage forms and therapeutic areas.

The company focuses on dose-form innovations to address unmet needs in underserved patient groups. Azurity utilizes data, analytics, and AI-driven tools to enhance market reach and support the development of complex dosage forms. Its product offerings include oral solutions, suspensions, and specialized formulations designed to improve medication accessibility and adherence. Azurity's growth strategy includes organic research and development, as well as strategic acquisitions, which have expanded its capabilities and product offerings to better serve patients with specialized needs.